TGA approves Descovy (emtricitabine with tenofovir alafenamide fumarate)

7 July 2016 - The TGA has approved Gilead Sciences' new dual combination product for patients with HIV infection.

The TGA approved Descovy on 1 July 2016 for use in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg.

View Descovy PI

Michael Wonder

Posted by:

Michael Wonder